#Metered Dose Inhalers

[jairapsi]

Mastering Metered Dose Inhalers at JAI

Dive into our comprehensive metered dose inhaler education program at JAiRespi. Learn the correct techniques and essential tips to manage your respiratory condition effectively. Our expert-led tutorials are designed to enhance your inhalation therapy, ensuring you get the maximum benefit from your medication. Visit us now for more details.

[kavehater]

Seeing that one girls’ note saying according to this uni size does matter has me rolling on the floor 😭😭😭

[shodansbabygirl]

I think branded patented medications are already awful enough but they should be illegal just for the fact that most pharmacies aren't actually carrying an AirSupra inhaler so I've been waiting a week for it and I started another heavily inflammation based asthma attack that Will Not Stop.

[plastparekh]

Medical Inhaler Manufacturer | Metered Dose Inhaler

We are India-based medical inhaler manufacturer company supplying asthma actuators, metered dose inhalers in India and exported all over the world! We certainly have the highest quality of testing standards. The vast range of expertise offers various different sizes that includes from 19 ml canisters. Simpler Operating Systems. Our Products offer Optimum quality performance. Customized solutions are offered for best packaging needs.

[macgyvermedical]

Fun (recent) Medical Technology History Facts

The first EKG was taken in 1901, the machine looked like this:

CPR was invented about 10 years after the defibrillator came into use (1960s vs 1970s).

The first CT scans on humans were taken in 1973. They took 1-2 hours to scan 8-12 images, which printed out on Polaroid film. They looked like this:

The first MRI machine image was taken in 1980. It was of a bell pepper:

The first bioethics committee determined who got to use the first 6 dialysis machines for chronic use in 1960 (dialysis was invented in the 1940s but was only used for acute care, not long-term).

Metered Dose Inhalers didn't exist until the 1950s.

Heart transplants and oral contraception were invented in the same decade- the 1960s

Routine handwashing in hospitals and food service didn't start until the 1980s.

We didn't know what viruses looked like until the 1970s.

Human insulin didn't exist until the 1980s (prior to that we only had pork and bovine insulins).

[averyghe]

Southern continent was the first place where the plant life emerged on Mars – from the magic of Yulakai, gurms crawled, herbs bloomed, and the grasses sprouted. The most common among all the large plants on the continent are Giris and Atmas, which were successfully domesticated and produced shadows in the gardens and the backyards all around the South. In the forrest corners and the meadows where those trees most often grow, they are accompanied by the many lesser herbs, the most noteworthy among which are certainly triflowers, known to be a medicinal herbs which can help with the headaches and inflamations, as well as whitflowers – known for their sweetness, and the fact that the sticky whiskers of an animal known as whitshel are resembling them to lure small insects.

On the outskirts of the Forrest you will see the blooming sprouts of Gramm’s treat – the plant known for the fact that it’s really liked by the gramhounds, who end up in trance after eating the sour yellow flowers. It is also true that by inhaling their pollen it is possible to feel lightheaded, up until the point of losing consciousness – that’s the reason why the large doses of the gramm’s treat pollen are used in the poisons, and pleasure powders used by Movats as well as wizards who believe that by mixing gramm’s treat with certain hallucinogens they can ascend in their understanding of magic.

Along side those plants there is venowing called that way for its form vaguely resembling green bird lying on the ground touching or eating it can result in stinging feeling on the skin – however, if prepared right venowing can be used in preparation of stews and even jams.

Starfluffs on their end are really great for creating the yarn out of them, so because of it they also were domesticated and now usually grown on the large plantations. They are also favourite food of bakais, and some other large herbivores.

But what should not be ever eaten is purple gurm – unlike other kinds of grum, this one is known to incredibly poisonous, even touching it can lead to the terrible consequences in the form in the form of skin burns, limb numbness, and in the end paralysis…

Over the herbs and bushes much larger plants are blooming – for example gigantic flowers of Kananti during the bloom season they are opening to release their spores in the air. It’s a beautiful site when the air is filled with the nearly glowing golden particles. However before blooming, Kananti can be used, on nearly all of their grow stages – juvenile sprouts are great to be prepared as garnish, stew, or given as food to the Woopas. Medium sized ones can be used make team as well as yellow and green dies. And in the end pollinating Kananti flowers can be used to make soothing mixtures, and potions against hair loss.

And one of the largest among all the plants and trees are trees of Paros that can grow up to thirty meters in height. They are also known as the Mast trees or Table trees as they are often used in the shipbuilding and exquisite carpentry…

[endcant]

i am so glad i kept my breathing mask & metered dose inhaler valved holding chamber & lung capacity trainer from the last time i had respiratory illness. its so good to have medical swag on hand actually

idk if i’ll be able to stream tomorrow 🥲

[that-one-sketch]

You are Worried about it

Asgore chuckles, “That’s what I thought too. Till he told me.” He pauses to deepen his voice again. “You are worried about. That means you will listen.”

Asgore starts to move his arms and body, as though to mimic someone of a stoic nature. “You will learn. You will adapt, and you will improve.”

Taking a pause to take in a deep breath, the large monster seems deep in thought. “Kings who are metered worried for his people, never protects them.”

Asgore’s large feet move into a march. Still mimicking someone and he leads off to the Judgment Hall.

“A king who never worries for his family, is never there for them.” A large hoofed hand pokes Clara’s nose. Making them giggle slightly.

“A king who dose not have worries, cannot help himself.”

Chara nods, understanding what he was saying. There is a soft quite as Asgore’s footsteps echo in the hall. As the get half way, Chara takes in a breath.

“What was Grandpa worried about?”

Asgore’s face widens slightly, as if, started by the question. He scrunches up his face in thought. Opening and closing his mouth as if his tongue has be come large lump in his mouth. He inhales as he pauses a little, half way in the golden hall. Asgore’s shoulders lift as he takes in a breath.

“He was worried about humans, and the war.” His eyes lost in thought on the tile floor. Seemingly finding them interesting. Then he continued.

“Then became worried for the human wizards.” Another long pause. It took Asgore some time before he spoke again. In a much more somber tone.

“Then it was my turn to worry.” The silence filled them once again, but not for long as he finished looking up at the window. Tuning his body to face the sunlight drifting in, “for him.” He Then turned to Chara. Their face silent, and in study. As though not wanting to interrupt the old monster.

“And now. For you.” He smiled. Chara smiled back, and with a slightly more straitened posture.

Little me moment——————————————

I will never forget what my upper class men has told me. As I am a 1st year, I remember talking to them about their projects. And I say something along the lines of “I don’t know if I will get to Sophomore year.” And they turn to look at me and they say, “You’er worrying about. You will make it. You want to know why?” I reply with a yes, they take a breath, “You are worried. That means you will listen. You will work. And you will improve. I have found that, those around me who don’t worry. Don’t improve. And they fail. You.” They take a pause before they finish. “Keep your worries. But don't overthink it.”

[mcatmemoranda]

From UpToDate

Asthma:

Acute exacerbation:

Mild to moderate exacerbations (initial home management): Note: Patients with worsening symptoms despite initial care should seek immediate medical attention (Ref).

Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): Oral inhalation: 2 to 4 inhalations every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed; if incomplete response, can lengthen interval to every 1 to 3 hours as needed (Ref).

Nebulization solution: Oral inhalation: 2.5 mg every 20 minutes for 3 doses; if good response, can lengthen interval to every 3 to 4 hours as needed; if incomplete response, can lengthen interval to every 1 to 3 hours as needed (Ref).

Moderate to severe exacerbations (management in primary or acute care settings): Note: For severe exacerbations, albuterol is used in combination with an inhaled short-acting muscarinic antagonist, and nebulized treatments are generally preferred (Ref).

Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): Oral inhalation: 4 to 10 inhalations every 20 minutes for 3 doses, then taper as tolerated (eg, to 2 to 4 inhalations every 1 to 4 hours as needed) (Ref). High doses are typically administered in a monitored setting.

Nebulization solution: Oral inhalation: 2.5 to 5 mg every 20 minutes for 3 doses, then taper as tolerated (eg, to 2.5 to 5 mg every 1 to 4 hours as needed). For critically ill patients, 10 to 15 mg may be administered by continuous nebulization over 1 hour via special apparatus (Ref).

IV continuous infusion [Canadian product]: Note: Reserve intravenous beta-agonists for those patients in whom inhaled therapy cannot be used reliably (Ref). Initial: 5 mcg/minute; may increase up to 10 to 20 mcg/minute at 15- to 30-minute intervals, if needed.

Intermittent symptom relief (alternative agent): Note: Use on an as-needed basis (reliever therapy) rather than regularly scheduled. For maintenance therapy, additional controller agents should be used (Ref).

Nebulized therapy may be preferable for patients who have more severe symptoms or who cannot effectively use an inhaler (Ref).

Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): Oral inhalation: 2 inhalations every 4 to 6 hours as needed (Ref); some experts recommend up to 4 inhalations every 4 to 6 hours for moderate to severe symptoms (Ref).

Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): Oral inhalation: 1 inhalation every 4 to 6 hours as needed.

Nebulization solution: Oral inhalation: 2.5 mg every 4 to 6 hours as needed (Ref).

Exercise-induced bronchoconstriction (prevention):

Metered-dose inhaler or dry powder inhaler (90 mcg/actuation): Oral inhalation: 2 inhalations 5 to 20 minutes prior to exercise (Ref).

Canadian formulation: Ventolin Diskus [Canadian product]: DPI (200 mcg/inhalation): Oral inhalation: 1 inhalation 15 minutes prior to exercise.

[jairapsi]

Metered Dose Inhaler Education

Gain confidence in using your metered dose inhaler education with the comprehensive education provided by JAI. Our step-by-step guidance ensures you understand the correct techniques for effective medication delivery, helping to improve your respiratory health and manage conditions like asthma or COPD. We offer personalized support, including tips on inhaler maintenance, troubleshooting, and proper dosage timing, ensuring that you get the most out of your treatment. Empower yourself with the knowledge to breathe easier and take control of your health.

[taimoorkhan]

Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways, leading to difficulty breathing. It is a common condition that affects people of all ages and can range from mild to severe. In severe cases, asthma can be life-threatening and require emergency treatment.

In the emergency department, the main goal of treatment is to relieve symptoms and restore normal breathing as quickly as possible. Established treatments for asthma in the emergency department include oxygen therapy, beta-agonists, anticholinergics, corticosteroids, and aminophylline.

Oxygen therapy is an important part of treatment for severe asthma. It is typically given through a face mask and is titrated to maintain a oxygen saturation (SpO2) of at least 92%. Beta-agonists, such as salbutamol, can be given through nebulization, a metered-dose inhaler (MDI), or intravenously (IV). Anticholinergics, such as ipratropium bromide, can be given through nebulization and may be administered every 2-6 hours. Corticosteroids, such as hydrocortisone or prednisone, can help reduce inflammation in the airways and may be given every 6 hours or at a dosage of 0.5mg/kg/day. Aminophylline is a bronchodilator that can be given as a loading dose of 6mg/kg followed by a continuous infusion of 0.5mg/kg/hr. It is important to monitor aminophylline levels and aim for a range of 30-80micromol/L.

There are also non-established treatments for asthma in the emergency department that may be used in certain cases. These include adrenaline, magnesium sulfate, heliox, ketamine, inhalational agents, leukotriene antagonists, and bronchoalveolar lavage (BAL). Adrenaline can be given through nebulization, subcutaneous injection, or IV infusion. Magnesium sulfate can be given as a 20-minute infusion of 5-10mmol, with higher dosages of up to 80mmol used in some cases. Heliox is a mixture of helium and oxygen that can reduce turbulent air flow and may be used in cases of severe asthma. Ketamine is an anesthetic that can be given as a continuous infusion at a dosage of 0.5-2mg/kg/hr. Inhalational agents, such as sevoflurane, can be used to help manage asthma, but require the use of an anaesthetic machine or a custom fitted ventilator. Leukotriene antagonists are a class of medications that may provide some benefit in chronic asthma. Bronchoalveolar lavage (BAL) involves the instillation of saline into the airways to clear mucous plugging, although it may transiently worsen bronchospasm.

In conclusion, the management of asthma in the emergency department involves the use of established treatments such as oxygen therapy, beta-agonists, anticholinergics, corticosteroids, and aminophylline, as well as non-established treatments that may be used in certain cases. The main goal is to relieve symptoms and restore normal breathing as quickly as possible.

[bestgenericmedicine]

https://bestgenericmedicine.com/product/asthalin-hfa-inhaler-100-mcg

A drug called asthalin inhaler 100 mcg is used to treat bronchospasm, a frequent symptom of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol, which is an active component and a member of the class of medications known as bronchodilators, is present in it.

In order to facilitate easier airflow into and out of the lungs, bronchodilators function by relaxing the muscles in the airways. Metered-dose inhalers, such as the Asthalin HFA inhaler, deliver a fixed dose of medication with each puff. Typically, it is used as a rescue inhaler to quickly alleviate symptoms including shortness of breath, wheezing, and tightness in the chest.

Company: Best Generic Medicine

URL: https://bestgenericmedicine.com

[plastparekh]

Nasal Spray Manufacturer | Nasal Spray

We are a quality Nasal Spray Manufacturer & supplier of nasal spray bottles. We are the preferred choice in the packaging industry and renowned for satisfactory results.We are the most reputable manufacturers and suppliers of Nasal Sprays. Having expertise in medical dispensing applications, we have the prime focus on precision. Standard protocols and high grade raw materials are few of our distinguished qualities.

[insightsbyskyquest]

COPD and Asthma Devices Market: Size, Share, and Growth Analysis 2031

Chronic Obstructive Pulmonary Disease (COPD) and asthma are two of the most prevalent respiratory diseases worldwide. Both conditions significantly impact patients' quality of life and are associated with substantial healthcare costs. With the increasing prevalence of these diseases, the demand for effective management devices is on the rise. This article explores the COPD and asthma devices market, focusing on size, share, and growth projections through 2031.

To Learn More About This Report, Request a Free Sample Copy - https://www.skyquestt.com/sample-request/copd-and-asthma-devices-market

Market Overview

The global market for COPD and asthma devices encompasses a range of products designed to assist in the management and treatment of these respiratory conditions. Key device categories include:

- Inhalers: Metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs).

- Nebulizers: Devices that convert liquid medication into mist for inhalation.

- Peak Flow Meters: Tools for measuring the peak expiratory flow rate (PEFR) in patients with asthma.

- Smart Devices: Digital inhalers and connected health platforms that monitor usage and medication adherence.

Market Size and Share

COPD and Asthma Devices Market was valued at USD 48.78 billion in 2023, to USD 71.52 Billion by 2031 at a CAGR of 4.90% during the forecast period (2024-2031).

Key Drivers of Growth

1. Rising Prevalence of Respiratory Diseases: The increasing incidence of asthma and COPD, driven by factors such as urbanization, pollution, and lifestyle changes, is a significant driver for the market.

2. Technological Advancements: Innovations in inhaler design, such as smart inhalers that provide real-time feedback, are enhancing patient adherence and outcomes.

3. Increased Awareness and Diagnosis: Growing awareness about respiratory diseases and improved diagnostic techniques are leading to early detection and treatment, thereby boosting demand for management devices.

4. Government Initiatives and Funding: Various governments and health organizations are investing in respiratory health initiatives, creating opportunities for market growth

5. Aging Population: The global population is aging, and older adults are more susceptible to respiratory diseases, further driving market demand.

COPD and Asthma Devices Market Segmental Analysis

Global COPD and Asthma Devices Market is segmented based on the product type, indication, distribution channel, and region.

Based on product type, global COPD and Asthma Devices Market is bifurcated into Inhalers and Nebulizers.

According to indication, COPD and Asthma Devices Market is segmented into Asthma and Chronic Obstructive Pulmonary Disease (COPD).

According to distribution channel, COPD and Asthma Devices Market is categorized into Retail Pharmacies, Hospitals and Online Pharmacies.

Based on Region, COPD and Asthma Devices Market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

COPD and Asthma Devices Market Top Player's Company Profiles - Smith’s Group PLC, GF Health Products, 3M Company, Aerogen, Inc., Baxter International Inc., Koninklijke Philips N.V. (Philips), Novartis AG, PARI medical Holding GMBH, Omron Healthcare, Invacare Corporation, Cipla Ltd., Consort Medical, Gerresheimer, NYPRO

Read COPD and Asthma Devices Market Today - https://www.skyquestt.com/report/copd-and-asthma-devices-market

Challenges

Despite the positive outlook, the COPD and asthma devices market faces several challenges:

- High Costs: The cost of advanced devices can be prohibitive for some patients and healthcare systems, potentially limiting market growth.

- Regulatory Hurdles: Stringent regulations and lengthy approval processes for new devices can delay market entry.

- Limited Access: In some regions, especially in developing countries, access to healthcare facilities and respiratory devices remains a challenge.

Future Outlook

The COPD and asthma devices market is poised for substantial growth through 2031, driven by technological innovations, increased awareness, and a rising patient population. As the market evolves, manufacturers are expected to focus on developing user-friendly, cost-effective, and technologically advanced devices to meet the needs of patients and healthcare providers. The COPD and asthma devices market is a dynamic and rapidly growing sector with significant opportunities for innovation and expansion. As healthcare continues to prioritize respiratory health, stakeholders in the market must adapt to changing patient needs and leverage technological advancements to improve treatment outcomes. With the right strategies, the industry is well-positioned for a successful future in addressing the challenges of respiratory diseases.